Drug Profile
KW 2149
Alternative Names: E 90/007; KT 6149Latest Information Update: 26 Sep 2006
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Class Cytostatic antibiotics; Mitomycins; Small molecules
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Sep 2006 Discontinued - Phase-II for Cancer in Japan (IV-injection)
- 26 Sep 2006 Discontinued - Phase-III for Cancer in European Union (IV-injection)
- 02 Oct 2001 No-Development-Reported for Cancer in European Union (IV-injection)